PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Update

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) was the target of a large increase in short interest in February. As of February 13th, there was short interest totaling 5,259 shares, an increase of 36.2% from the January 29th total of 3,860 shares. Based on an average trading volume of 1,887 shares, the short-interest ratio is currently 2.8 days. Approximately 0.0% of the shares of the stock are short sold. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 1,887 shares, the short-interest ratio is currently 2.8 days.

PureTech Health Price Performance

PureTech Health stock traded down $0.15 during trading hours on Wednesday, hitting $17.10. 154 shares of the stock were exchanged, compared to its average volume of 4,029. The business’s 50-day moving average is $17.93 and its two-hundred day moving average is $17.45. PureTech Health has a 12 month low of $13.30 and a 12 month high of $20.00.

Hedge Funds Weigh In On PureTech Health

Several institutional investors have recently bought and sold shares of PRTC. Lansdowne Partners UK LLP bought a new stake in shares of PureTech Health during the third quarter worth $260,973,000. Pentwater Capital Management LP lifted its position in PureTech Health by 50.0% during the 3rd quarter. Pentwater Capital Management LP now owns 75,000 shares of the company’s stock worth $1,388,000 after buying an additional 25,000 shares in the last quarter. Diadema Partners LP acquired a new position in PureTech Health during the 2nd quarter worth about $126,000. Finally, Persistent Asset Partners Ltd bought a new stake in PureTech Health during the 2nd quarter worth about $29,000. Institutional investors own 0.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of PureTech Health in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.